Collegium Pharmaceutical, Inc. (COLL) Q4 FY25 Earnings Call

Jornay growth is accelerating, but 2026 consolidated revenue and EBITDA guidance implies meaningful deceleration.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-27
Length39 minutes
EPS$1.85
EPS consensus$2.01
Revenue$209.4M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All COLL earnings ยท Back to COLL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.